Stockdale Lab In the Division of Oncology

Publications: Book chapters & review articles


1. Klinman NR, Segal GP, Gerhard W, Braciale T and Levy R:Obtaining homogeneous antibody of desired specificity from fragment cultures.Antibodies in Human Diagnosis and Therapy.E Haber and RM Krause (eds.),Raven Press, NY, pp. 225236, 1977.


2. Weissman IL, Warnke R, Butcher EC, Rouse R and Levy R:The lymphoid system:Its normal architecture and the potential for understanding the system through the study of lymphoproliferative diseases. Human Pathology, Volume 9, Number 1, pp. 2545, January 1978.

3. Kaplan HS and Levy R, eds. Malignant Lymphoma.UICC Technical Report Series, Volume 37, Geneva, 239p, 1978.

4. Levy R, Dilley J and Lampson LA:Human normal and leukemia cell surface antigens.Mouse monoclonal antibodies as probes.Lymphocyte Hybridomas:Current Topics In Microbiology and Immunology, Volume 81.F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin,pp. 164169, 1978.

5. Levy R, Dilley J, Siora K and Kucherlapati R.Mouse-human hybridomas.The conversion of non-secreting human B cells into Ig secretors.Lymphocyte Hybridomas:Current Topics in Micrology and Immunology, Volume 81.F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin,pp. 170172, 1978.


6. Goodenow RS, Brown S, Levy R and Kaplan HS:Partial characterization of the virion proteins of a type-C RNA virus produced by a human histiocytic lymphoma cell line.Viruses In Naturally Occurring Cancers.Cold Spring Harbor Conferences on Cell Proliferation, Volume 7, Cold Spring Harbor Laboratory,pp. 737752, 1980.

7. Levy R, Dilley J, Brown S and Bergman Y:Mouse x human hybridomas.Monoclonal Antibodies, Chapter 9. RH Kennett, TJ McKearn and KB Bechtol (eds.), Plenum Publishing Corporation,New York, pp. 137249, 1980.

8. Warnke R and Levy R:Tissue section immunologic methods in lymphomas.Chapter 12.Diagnostic Immunohistochemistry, pp. 203211, 1980.


9. Levy R, Hatzubai A, Brown S, Maloney D and Dilley J:Immunoglobulin idiotype:A tumor-specific antigen for human B-cell lymphomas. Malignant Lymphomas.Chapter 5.Academic Press, Inc., pp. 95105, 1982.

10.  Fox R, Baird S, Kung P, Levy R and Royston I:Cell surface antigens on normal and neoplastic human lymphoid cells. Human Cancer Markers.Chapter 2. S Sell and B Wahren (eds.), Humana Press,pp. 3368, 1982.

11.  Miller RA, Stratte PT, Oseroff AR, Link MP and Levy R:Treatment of human T-cell lymphomas and leukemias with monoclonal anti-T cell antibodies. Hybridomas in Diagnosis and Treatment.Ortho Pharmaceutical Ltd., Canada,pp. 105110, 1982.

12.  Levy R:Monoclonal antibodies in clinical trials of human T and B cell malignancies.Biological Response Modifiers Program.Proceedings of the Retreat on Monoclonal Antibodies in Therapeutic Trials.Frederick, Maryland,pp. 5355, 1982.

13.  Miller RA, Maloney D, Warnke R, McDougall R, Wood G, Kawakami T, Dilley J, Goris ML and Levy R:Considerations for treatment with hybridoma antibodies.Hybridomas in Cancer Diagnosis and Treatment.MS Mitchell and HF Oettgen (eds.), Raven Press,New York, pp. 133145, 1982.

14.    Levy R:Monoclonal antibodies:Sixth Annual Cancer Symposium, Scripps Memorial Hospital, 1982.


15.  Finn OJ, Sung E, Jones P and Levy R:Two alpha chains and three beta chains of human Ia antigen. In:Ir Genes: Past Present and Future.CW Pierce, SE Cullen JA Kapp, BD Schwartz and DC Shreffler, editors.Humana Press, Clifton, NJ, pp. 203207, 1983.

16.  Levy R, Stratte PT, Link MP, Oseroff A, Maloney DG and Miller RA:Monoclonal antibodies in leukemia therapy.Leukemia Research:Advances in Cell Biology and Treatment.SB Murphy and JR Gilbert, editors.Elsevier Science Publishing Co., pp. 269279, 1983.

17.  Hurley CK, Nunez G, Winchester R, Finn O, Levy R, Stastny P and Capra JD:Partial structural characterication of human HLA-DR subsets using monoclonal antibodies.Hybridomas and Cellular Immortality.BH Tom and JP Allison, editors.Plenum Publishing Corporation, NY, pp. 83100, 1983.

18.  Levy R, Miller RA, Stratte PT, Maloney DG, Link MP, Meether TC, Oseroff A, Thielemans K and Warnke R:Therapeutic trials of monoclonal antibody in leukemia and lymphoma:Biologic considerations.Monoclonal Antibodies and Cancer.RE Langman, IS Trowbridge and R. Dulbecco, editors. Academic Press, NY, pp. 516, 1983.

19.  Levy R and Miller RA:Biological and clinical implications of lymphocyte hybridomas:Tumor therapy with monoclonal antibodies.Ann Rev Med 34:107116, 1983.

20.  Levy R:Monoclonal antibodies in cancer therapy.Clinical Immunology Today, No. 3., pp. 17.July 1983.


21.  Levy R, Stratte P, Link M, Maloney DG, Oseroff Aand Miller RA:Monoclonal antibodies to human lymphocytes.Monoclonal Antibodies and Functional Cell Lines.Chapter 8.RH Kennett, KB Bechtol and TJ McKearn (eds.), Plenum Publishing Corporation, New York, pp. 193214, 1984.


22.  Levy R:Biologicals for cancer treatment:Monoclonal antibodies.Cancer:Progress and Prospects XXVII.Hospital Practice,pp. 6792, November 15, 1985.

23.  Lowder JN and Levy R:Monoclonal antibodiestherapeutic and diagnostic uses in malignancy.Western J Med 143:810-818, December 1985.

24.  Miller RA and Levy R:Functional and surface marker characteristics.Immunoglobulin:ATumor Specific Antigen for Human B Cell Lymphoma.Academic Press, 1985.

25.  Lowder JN, Meeker TC and Levy R:Monoclonal antibody therapy of lymphoid malignancy. Cancer Surveys 4:359375, 1985.


26.  Levy R, Meeker T, Lowder J, Maloney D, Thielemans K, Gralow J, Warnke RA, Miller RA, Cleary ML and Sklar J:The immunobiology of B cell lymphoma studies with anti-idiotype antibodies.Symposium on Fundamental Cancer Research, Vol. 38, pp. 261268,1986, University of Texas System Cancer Center.


27.  Levy R:Monoclonal antibodies:Clinical trials and new insights into tumour biology.A Perspective on Biology and Medicine in the Twenty-First Century, Royal Society of Medicine Services Limited, Series 121, pp. 103112, 1987.

28.  Levy R, Levy S, Brown SL, Kon S and Carroll W:Anti-idiotype antibodies reveal the existence of somatic mutation in human B cell lymphoma. Monographs in Allergy. P Dukor, LA Hanson, P Kallos, F Shakib, Z Trnka and BH Waksman (eds.), S. Karger, Basel, 22:194203, 1987.

29.  Levy R, Levy S, Cleary ML, Carroll W, Kon S, Bird J and Sklar J:Somatic mutation in human B cell tumors. Immunological Reviews 96:4358, Munksgaard, Cophenhagen, 1987.

30.  Levy R:Will monoclonal antibodies find a place in our therapeutic armamentarium?J Clin Oncology 5:527529.


31.  Brown SL, Miller RA and Levy R:Anti-idiotype antibody therapy of B-cell lymphoma. Seminars in Oncology 16:199210, 1989.

32.Campbell MJ, Esserman L, Byars NE, Allison AC and Levy R:Development of a new therapeutic approach to B cell malignancy.The induction of immunity by the host against cell surface receptor on the tumor.Intern. Rev. Immunol 4:251, 1989.


33.  Levy, R. and Miller RA:Therapy of lymphoma directed at idiotypes. NCI Monographs, 10:6168, 1990.

34.  Miller R and Levy R:Radiolabeled antibodies:Another form of cytotoxic treatment.J Clin Onc 9:537538, 1990.

35.  Kwak LW, Campbell M, and Levy R.Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma:Initial Studies in a murine model.Cancer Detection and Prevention 15:323325, 1990.

36.  Levy R:Anti-idiotypes:Therapy and somatic mutation of human B cell tumors.Immunology for the Practicing Physician.Bozell, Jacobs, Kenyon and Echardt, Inc., New York, 1990.

37.Campbell MJ, Brown SL and Levy R:Tumor immunology and immunotherapy.Immunology Scope Monograph.Upjohn Co., Kalamazoo, Michigan, 1990.

38.  Levy R and Miller RA:Antibodies in cancer therapy:B cell lymphomas.Biologic Therapy of Cancer:Principles and Practice, S Hellman, V DeVita and SA Rosenberg (eds), Lippincott, 1990.


39.  Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, Levy R, Miller R, Fisher D, Matthews D, and Bernstein ID:Radiolabeled antibody therapy of human B cell lymphomas.Immunobiology of Proteins and Peptides VI, M.Z. Atassi (ed), Plenum Press, 1991.


40.  Bahler DW, Zelenetz AD, Chen TT and Levy R. Antigen selection in human lymphomagenesis.Cancer Research (Suppl) 52:5547a5551s, 1992.

41. Maloney DG, Levy R, and Miller RA.Monoclonal anti-idiotype antibody therapy of lymphoma.Biologic Therapy of Cancer Update, V. T. DeVita, S. Hellman, and S. A. Rosenberg ( eds.), J.B. Lippincott Company, Philadelphia, PA, 1992.


42. Renschler MF and Levy R.Overcoming the limitations of chemotherapy in the treatment of B-cell Non-Hodgkin's lymphomasAn approach using radiolabeled peptide ligands.Western J. Med. 158:530532, 1993.


43. Maloney DG, Levy R, and Campbell MJ.Antibodies.The Molecular Basis of Cancer,J. Mendelsohn, PM Howley, MA Israel, LA Liotta (eds.), WB Saunders, Harcourt Brace Jovanovich, Inc. ,Philadelphia, PA. 1994


44. Renschler MF, Dower WJ, Levy R.Identification of Peptide Ligands for the Antigen Binding Receptor Expressed on Human B-Cell Lymphomas.Combinatorial Peptide Libraries, Methods in Molecular Biology, Humana Press, Inc., Totowa, NJ. 1995


45.  Hsu F, Engleman E and Levy R.Dendritic cells and their application in immunotherapeutic approaches to cancer therapy. PPO Updates, Vol 11, No. 5, 1997

46. Reichardt V, Okada C, Stockerl-Goldstein K, Bogen B, and Levy R.Rationale for adjuvant idiotypic vaccination after high dose therapy for multiple myeloma. Biology of Blood & Marrow Transplantation, 3:157-163, 1997

47. Maecker HT, Syrengelas A and Levy R.Cytokine fusion constructs as DNA vaccines against tumors.Methods in Molecular Medicine, 29:221-239, 1997


48. Timmerman J and Levy R.Melanoma vaccines: Prim and proper presentation.Nature Medicine, 4:6-7, 1998.


49. Timmerman JM and Levy R.Dendritic cell vaccines for cancer immunotherapy.Ann Rev of Med, 50:507-529, 1999.

50.    Levy R. Karnofsky Lecture: Immunotherapy of lymphoma. J. Clinical Oncology. 17(11 Suppl):7-12, 1999.

51.    Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR Jr, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. Related Articles.The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes.Cold Spring Harb Symp Quant Biol. 64:71-8, 1999.


52.    Levy, R. A perspective on monoclonal antibody therapy: Where we have been and where we are going. Seminars in Hematology, 37 (suppl. 7), 2000.

53.    Timmerman J, and Levy R. The history of the development of vaccines for the treatment of lymphoma. Clinical Lymphoma, 1(2): 129-139, 2000.

54.    Levy, R. Monoclonal antibodies for the treatment of lymphoma; many different ways to use a new modality. Hematology 2000, 397-400, 2000.


55.    Reddy SA, Okada C, Wong C, Bahler D, Levy R. T cell antigen receptor vaccines for active therapy of T cell malignancies. Cutaneous T Cell Lymphoma: Basic and Clinically Relevant Biology, Ann N Y Acad Sci. 941:97-105, 2001.

56.    Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J.Immunotherapy of Non-Hodgkin's Lymphomas, Hematology (Am Soc Hematol Educ Program)221-40, 2001.


57.    Lossos IS and Levy, R.Higher-grade transformationof follicle center lymphoma:phenotypic tumor progressionassociated with diverse genetic lesions.Seminars in Cancer Biology. In press 2002.


58.    Lossos IS and Levy R.Diffuse Large B-cell Lymphoma:insights gained from gene expression profiling.International Journal of Hematology. In press.


Footer Links: